Martins Maria Alcina, de Castro Bastos Lúcia, Tonussi Carlos Rogério
Department of Pharmacology, Federal University of Santa Catarina, Campus Universitário-Trindade, Florianópolis, Santa Catarina.
J Pain. 2006 Feb;7(2):100-7. doi: 10.1016/j.jpain.2005.09.002.
Formalin (0.25, 0.5, 3, and 5%) injected into the knee joint of rats induced a dose-dependent nociception that was featured by 2 phases of intense guarding behavior of the affected limb, interposed by a period of quasinormal gait (quiescent phase). The guarding behavior during a period of forced gait was measured by the total time the paw of the affected limb was not in contact with the surface of a revolving cylinder (paw elevation time [PET]). Pretreatment with morphine (4 mg/kg, subcutaneously) reduced PET in both nocifensive phases, and naloxone (1 mg/kg, subcutaneously) antagonized morphine's effect. The cyclooxygenase inhibitor diclofenac (5 mg/kg, intraperitoneal) reduced only the second phase of nocifensive responses. A low dose of the benzodiazepine midazolam (0.25 mg/kg, intraperitoneal) significantly reduced only the second phase of response, but a higher dose (1 mg/kg, intraperitoneal) had no effect. A subconvulsant, anxiogenic dose of pentylenetetrazol (30 mg/kg, intraperitoneal) also did not affect the PET increase induced by formalin. The antihistamine meclizine (2.5 mg/kg, intraperitoneal) caused an increase of the response in the second phase, but a higher dose (7.5 mg/kg, intraperitoneal) caused inhibition. The peripheral antihistamine loratadine (5 and 10 mg/kg, intraperitoneal) also caused an increase of the second phase. Neither antihistamine altered the first phase of PET. These results reproduced previous findings with classical analgesics in formalin-induced nociception. However, the pronociceptive effect of antihistamines, and the antinociceptive effect of midazolam observed here suggest that formalin-induced incapacitation introduces new characterists of nociceptive system that may complement the study of analgesics.
Anxiety is thought to influence pain experience in an opposing manner depending on nociception originates in cutaneous or deep somatic/visceral tissues. The present formalin-induced nociceptive test may help to predict more reliably the pain-killing effect of new pharmacologic strategies, with classical or nonclassical mechanisms, for the treatment of clinically relevant pains, which are generally originated in deep structures.
将福尔马林(0.25%、0.5%、3%和5%)注入大鼠膝关节会诱发剂量依赖性伤害感受,其特征为受影响肢体出现两个阶段的强烈保护性动作,中间夹杂一段近似正常步态的时期(静止期)。在强制步态期间,通过受影响肢体爪子不接触旋转圆柱体表面的总时间(爪子抬高时间[PET])来测量保护性动作。吗啡(4毫克/千克,皮下注射)预处理可降低两个伤害感受阶段的PET,而纳洛酮(1毫克/千克,皮下注射)可拮抗吗啡的作用。环氧化酶抑制剂双氯芬酸(5毫克/千克,腹腔注射)仅降低伤害感受反应的第二阶段。低剂量苯二氮䓬类药物咪达唑仑(0.25毫克/千克,腹腔注射)仅显著降低反应的第二阶段,但高剂量(1毫克/千克,腹腔注射)则无作用。亚惊厥剂量、致焦虑剂量的戊四氮(30毫克/千克,腹腔注射)也不影响福尔马林诱导的PET增加。抗组胺药美克洛嗪(2.5毫克/千克,腹腔注射)导致第二阶段反应增加,但高剂量(7.5毫克/千克,腹腔注射)则导致抑制。外周抗组胺药氯雷他定(5和10毫克/千克,腹腔注射)也导致第二阶段增加。两种抗组胺药均未改变PET的第一阶段。这些结果重现了先前使用经典镇痛药在福尔马林诱导的伤害感受中的发现。然而,此处观察到的抗组胺药的促伤害感受作用和咪达唑仑的抗伤害感受作用表明,福尔马林诱导的功能丧失引入了伤害感受系统的新特征,这可能补充了镇痛药的研究。
焦虑被认为会以相反的方式影响疼痛体验,这取决于伤害感受起源于皮肤还是深部躯体/内脏组织。目前的福尔马林诱导的伤害感受测试可能有助于更可靠地预测具有经典或非经典机制的新药物策略对临床上相关疼痛(通常起源于深部结构)的止痛效果。